Psoriasis drugs dominated the TV pharma ad landscape in March, as Johnson & Johnson’s Tremfya and AbbVie’s Skyrizi secured the top two spots in iSpot.tv’s ad rankings. The two drugs rose up the list ...

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...

After a record-setting October that easily dwarfed all preceding months in the year, TV drug ad spending found a happy medium in November. Last month, drugmakers shelled out a combined $277.3 million ...

“Treatment with guselkumab led to significant improvement in the chronic symptoms of ulcerative colitis with the capability of normalising the appearance of the intestinal lining,” said Laurent Peyrin ...

TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...

"The Week 12 results from the ASTRO study build on data from the QUASAR study demonstrating that both guselkumab SC and IV induction achieved clinically differentiated results in patients with ...